Biogen (BIIB) reported third-quarter 2026 revenue of $2.804 billion, up 11% from $2.535 billion a year earlier. The company posted a GAAP net loss attributable to Biogen of $20.6 million, or $0.14 per diluted share, compared with net income of $466.5 million, or $3.17 per diluted share, in the prior-year quarter.
Growth Portfolio revenue totaled $1.26 billion, up 49% year over year, including the first full quarter of contributions from acquired Apellis products. Biogen raised the lower end of its full-year 2026 reported non-GAAP diluted EPS guidance to $12.20 to $13.00.
- Total product revenue was $2.089 billion, up 13% year over year.
- Rare disease revenue increased 27% to $676 million, while specialized immunology revenue totaled $243 million.
- GAAP acquired IPR&D, upfront and milestone expense was $284 million, primarily related to the RayThera acquisition.
- Biogen ended Sept. 30 with approximately $1.3 billion in cash and cash equivalents and approximately $7.7 billion in total debt.
$BIIB Insider Trading Activity
$BIIB insiders have traded $BIIB stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $BIIB stock by insiders over the last 6 months:
- LLOYD MINOR has made 0 purchases and 2 sales selling 1,186 shares for an estimated $239,749.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$BIIB Hedge Fund Activity
We have seen 519 institutional investors add shares of $BIIB stock to their portfolio, and 398 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 5,409,698 shares (+42.2%) to their portfolio in Q2 2026, for an estimated $1,168,819,349
- JPMORGAN CHASE & CO added 1,823,140 shares (+inf%) to their portfolio in Q2 2026, for an estimated $393,907,628
- PACER ADVISORS, INC. added 1,122,981 shares (+inf%) to their portfolio in Q2 2026, for an estimated $242,631,274
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,117,663 shares (+inf%) to their portfolio in Q2 2026, for an estimated $241,482,267
- VAN ECK ASSOCIATES CORP removed 981,752 shares (-90.9%) from their portfolio in Q2 2026, for an estimated $212,117,337
- POINT72 ASSET MANAGEMENT, L.P. removed 721,468 shares (-89.1%) from their portfolio in Q2 2026, for an estimated $155,880,376
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 664,588 shares (-85.4%) from their portfolio in Q2 2026, for an estimated $143,590,883
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$BIIB Congressional Stock Trading
Members of Congress have traded $BIIB stock 7 times in the past 6 months. Of those trades, 4 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $BIIB stock by members of Congress over the last 6 months:
- REPRESENTATIVE MARIA ELVIRA SALAZAR has traded it 5 times. They made 3 purchases worth up to $130,000 on 05/12, 05/11 and 2 sales worth up to $65,000 on 09/24, 06/02.
- REPRESENTATIVE KEVIN HERN sold up to $15,000 on 08/18.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 06/05.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
